EP1675604A1 - Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii) - Google Patents

Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii)

Info

Publication number
EP1675604A1
EP1675604A1 EP04769072A EP04769072A EP1675604A1 EP 1675604 A1 EP1675604 A1 EP 1675604A1 EP 04769072 A EP04769072 A EP 04769072A EP 04769072 A EP04769072 A EP 04769072A EP 1675604 A1 EP1675604 A1 EP 1675604A1
Authority
EP
European Patent Office
Prior art keywords
root
mixture
tincture
temperature
fact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769072A
Other languages
German (de)
French (fr)
Inventor
Vladimir Leko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1675604A1 publication Critical patent/EP1675604A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/14Cupressaceae (Cypress family), e.g. juniper or cypress
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/45Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/51Gentianaceae (Gentian family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/60Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605Morus (mulberry)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/84Valerianaceae (Valerian family), e.g. valerian
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1664Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • This invention refers to the field of pharmacy, and more closely, it refers to the medicament against diabetes mellitus type I and II, and even more precisely, it refers to the medicament against diabetes mellitus type based on a herbal composition as an active substance.
  • the subject invention is marked with the classification symbol A 61 K 35/78- Medical preparations containing substances or products of their reactions with undefined composition, whereby substances from herbs are in question.
  • a technical problem, the solution of which is disclosed in this patent application, consists in finding cheaper and simplier way of obtaining and optimisation of proces of production substance that is disclosed within patent application with publication No. WO 99/55351.
  • Unexpectitly, obtained composition has shown improved efficiency in treatment of diabetes mellitus type II in comparation with composition described in aforsaid patent application. Also surprisigly, in contrast to composition dislosed in WO 99/55351, according to present invention obtained composition has biological activity against diabetes mellitus type I as well.
  • 99/55351 comprises evaporation in the vacuum in the timely linear temperature gradient, following with, by liquid air, freezing of evaporated suspension on -186°C, with lyophilization as last step in process. It was been found that amount of obtained active substance substantially vary with small variation of timely linear temperature gradient substantially. Further, freezing of evaporated suspension on -186°C causes quality problems (namely obtained active substance in hygroscopic) and cost of production final product becomes unexpectedly high. Finally, implementetion of high pressures can cause plastic deformation of particles and deformation of intramolecular forces. As consequence biological activity can be damaged and quality fluctuation of final product, that was noticed, will be developed.
  • zeolite as compound in pharmaceutical preperation disclosed in WO 99/55351 often comprises Pb2 ⁇ s. Purification of zeolite from Pb2 ⁇ 5 traces makes final product production cost higher.
  • zeolite was changed by root of chicory, and instead of natural miccrocellulose in pharmaceutical preparation, according to the invention, pulvis powder of herbal composition described in patent application WO 99/55351 was charged.
  • active substance is obtained from extract made from herbal composition that comprises following usitnjeni and dried ingredients:
  • centaury Plant of centaury (Centaurii umbellatum, Gentianaceae) 10-15% by weight (wt.) root of dandelion (Teraxacum officinale, Asteraceae) 6-12 % by wt. fruit of juniper (Juniperi communis L., Cupresaceae) 5-8% by wt. plant of nettle (Urticae dioidca L, Urticaceae) 5- 10% by wt. root of nettle (Urticae dioica L, Urticaceae) 5-10% by wt. root of chicory (Cichorium intybus L, Cichoriaceae) 12-20% by wt.
  • the active substance from the herbal composition is obtained in the following way: the herbal composition which is made of dried and ground to 40 ⁇ 5 mesh ingredients is to be covered in 60% ethanol at the room temperature. For the purpose of extraction, the mixture is left to rest for 28 days in a covered container, at the room temperature and pressure.
  • the herbal tincture is then obtained by decanting the liquid above the sediment.
  • the alcoholic tincture obtained in that way was exposed to whirling spray granulation, with spraying with anhydrous gas under pressure 1-3 barr, during 30-40 minutes.
  • Temperature of gas is at least 10°C higher than entering temperature of the tincture. Gas was provided by two-phase nozzle. Entering tempeature of tincture is, in prefe ed embodyment of the invention, 25 ⁇ 5° C, and temperature of the gas is 48 ⁇ 3° C.
  • Gas used for spraying can be oxigen.
  • Active substance obtained by aforesaid process has to be mixed, until homogeneous mixture, with pulvis powder of herbal composition, root of chicory and Mg-stearate to for obtaining pharmaceutical preparation.
  • Steps needed for active principle preparation and for preparation of pharmaceutical preparation are as follows:
  • centaury Centaurii umbellatum, Gentianaceae 10- 15% by weight (wt.) root of dandelion (Taraxacum officinale, Asteraceae) 6- 12 % by wt. fruit of juniper (Juniperi communis L, Cupresaceae) 5-8 % by wt. plant of nettle (Urticae dioica L, Urticaceae) 5-10 % by wt. root of nettle ( Urticae dioica L, Urticaceae) 5- 10 % by wt. root of chicory (Cichorium intybus L, Cichoriaceae) 12-20 % by wt.
  • Obtained alcoholic tincture is entered to apparatus for whirling spray granulation on temperature of 25 ° C.
  • apparatus alcoholic tincture is to be sprayed with anhydrous air, which has a temperature around 48 ° C. Air was provided in the apparatus with two phase nozzle.
  • apparatus alcoholic tincture has to be increased in density for factor 5. Spaying with air is applied under pressure of 3 barr. All procedure can be done with WSG-GLATT-50. 282 mg of alcoholic extract produces 56,4 mg dried powder of active substance.
  • capsules can consist 200 mg or 480 mg pharmaceutical preparation described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Subject matter of this application is obtaining of active principle and pharmaceutical preparation from herbal mixture comprising following dried and ground ingredients: plant of centaury (Centaurii umbellatum, Gentianaceae) 10-15% by weight (wt.) root of dandelion (Teraxacum officinale, Asteraceae) 6-12 % by wt. fruit of juniper (Juniperi communis L, Cupresaceae) 5-8 % by wt. plant of nettle (Urticae dioica L, Urticaceae) 5-10 % by wt. root of nettle (Urticae dioica L, Urticaceae) 5-10 % by wt. root of chicory (Cichorium intybus L, Cichoriaceae) 12- 20 % by wt. leaf of black mulberry (Morus nigra L, Moraceae) 5-10 % by wt. flower of yarrow (Achilleae millefolium L, Asteraceae) 2-5 % by wt. leaf of bilberry (Vaccinium myrtillus L, Ericaceae) 4-10 % by wt. pod of beans (Phaseolus vulgaris L, Fabaceae) 10-20 % by wt. and root of valerian (Valeriana officinalis L, Valerianaceae) 5-10 % by wt wherein each percentage refers to the total mass of the dried ingredients in the composition, at room temperature, extraction of this mixture in a covered container at the room temperature and pressure for 28 days, decantation of upper layer, filtration of lower layer comprising increasing the density of the herbal mixture by whirling spray granulation with spraying with gas under pressure 1-3 barr, through 30-40 minutes, with provision that temperature of anhydrous gas has to be at least 10° C higher than entering temperature of tincture.

Description

CAPSULATED HERBAL COMPOSITION AS AUXLLARY MEDICAMENT AGAINST DIABETES MELLITUS TYPE (I) AND (II)
FIELD WHICH THE INVENTION REFERS TO
This invention refers to the field of pharmacy, and more closely, it refers to the medicament against diabetes mellitus type I and II, and even more precisely, it refers to the medicament against diabetes mellitus type based on a herbal composition as an active substance.
According to the International Classification of Patents, the subject invention is marked with the classification symbol A 61 K 35/78- Medical preparations containing substances or products of their reactions with undefined composition, whereby substances from herbs are in question.
TEHNICAL PROBLEMS
A technical problem, the solution of which is disclosed in this patent application, consists in finding cheaper and simplier way of obtaining and optimisation of proces of production substance that is disclosed within patent application with publication No. WO 99/55351. Unexpectitly, obtained composition has shown improved efficiency in treatment of diabetes mellitus type II in comparation with composition described in aforsaid patent application. Also surprisigly, in contrast to composition dislosed in WO 99/55351, according to present invention obtained composition has biological activity against diabetes mellitus type I as well.
STATE OF THE ART
Process for production active substance that can be used in treatment of diabetes mellitus type II from herbal composition was disclosed by patent application WO 99/55351. In the same patent application pharmaceutical preparation that comprises active substance, natural microcelullose, natural zeolite, monosaccharide and Mg state in following portions 16,7 : 22,2 : 50,0 : 9,7 : 1,4 was disclosed. DETAILED DESCRIPTION OF INVENTION
Process of production of an active substance according to the patent application WO
99/55351 comprises evaporation in the vacuum in the timely linear temperature gradient, following with, by liquid air, freezing of evaporated suspension on -186°C, with lyophilization as last step in process. It was been found that amount of obtained active substance substantially vary with small variation of timely linear temperature gradient substantially. Further, freezing of evaporated suspension on -186°C causes quality problems (namely obtained active substance in hygroscopic) and cost of production final product becomes unexpectedly high. Finally, implementetion of high pressures can cause plastic deformation of particles and deformation of intramolecular forces. As consequence biological activity can be damaged and quality fluctuation of final product, that was noticed, will be developed.
Except aforesaid, it was been noticed that zeolite as compound in pharmaceutical preperation disclosed in WO 99/55351 often comprises Pb2θs. Purification of zeolite from Pb2θ5 traces makes final product production cost higher.
Listed problems are removed by less aggressive method for preparation of active substance and pharmaceutical preparation and by change of carrier, punila and other auxiliary substances. Namely, zeolite was changed by root of chicory, and instead of natural miccrocellulose in pharmaceutical preparation, according to the invention, pulvis powder of herbal composition described in patent application WO 99/55351 was charged.
With this elements all aforsaid problems of invention disclosed in cited application are removed.
Above that, unexpectidlly was found, in test on volontires, 7- 10% better biological activity of preparation obtained on way that was dislosed in present invention.
According to this invention active substance is obtained from extract made from herbal composition that comprises following usitnjeni and dried ingredients:
plant of centaury (Centaurii umbellatum, Gentianaceae) 10-15% by weight (wt.) root of dandelion (Teraxacum officinale, Asteraceae) 6-12 % by wt. fruit of juniper (Juniperi communis L., Cupresaceae) 5-8% by wt. plant of nettle (Urticae dioidca L, Urticaceae) 5- 10% by wt. root of nettle (Urticae dioica L, Urticaceae) 5-10% by wt. root of chicory (Cichorium intybus L, Cichoriaceae) 12-20% by wt. leaf of black mulberry (Morus nigra L, Moraceae) 5- 10% by wt. flower of yarrow (Achilleae millefolium L, Asteraceae) 2-5% by wt. leaf of bilberry (Vaccinium myrtillus L, Ericaceae) 4-10% by wt. pod of beans (Phaseolus vulgaris L, Fabaceae) 10-20% by wt. and root of valerian (Valeriana ojficinalis L, Valerianaceae) 5-10% by wt. wherein each percentage refers to the total mass of the dried ingredients in the composition.
According to the invention, the active substance from the herbal composition is obtained in the following way: the herbal composition which is made of dried and ground to 40±5 mesh ingredients is to be covered in 60% ethanol at the room temperature. For the purpose of extraction, the mixture is left to rest for 28 days in a covered container, at the room temperature and pressure. The herbal tincture is then obtained by decanting the liquid above the sediment. The alcoholic tincture obtained in that way was exposed to whirling spray granulation, with spraying with anhydrous gas under pressure 1-3 barr, during 30-40 minutes. Temperature of gas is at least 10°C higher than entering temperature of the tincture. Gas was provided by two-phase nozzle. Entering tempeature of tincture is, in prefe ed embodyment of the invention, 25 ± 5° C, and temperature of the gas is 48 ± 3° C. Gas used for spraying can be oxigen.
Active substance obtained by aforesaid process has to be mixed, until homogeneous mixture, with pulvis powder of herbal composition, root of chicory and Mg-stearate to for obtaining pharmaceutical preparation.
Unexpectedly, it was been shown by comparative tests that on this way prepared pharmaceutical composition has 7- 10% better efficiency in lowering blood glucose level than preparation disclosed in patent application WO 99/55351. To conclude, with less aggressive process of obtaining and with change of zeolite with chicory root, and with change of natural microcellulosse with pulvis powder of mixture described within patent application WO 99/55351, as well as with grinding herbal mixture before treatment with 60% alcohol (ethanol) up to 40 ± 5 mesh pharmaceutical preparation with same active principle, but with improved biological activity for 7- 10 % in relation to preparation disclosed in previous application, was obtained.
Except described effect, it was been noticed that pharmaceutical preparation according to this invention can be used for treatment diabetes mellitus type I, as well.
DESCRIPTION OF ONE EMBODIMENT OF INVENTION
Described embodiment of invention that follows could not in any possible way act in direction to narrow subject matter of invention.
Steps needed for active principle preparation and for preparation of pharmaceutical preparation are as follows:
1) Adding 7,2 kg of 60% of ethyl alcohol to the each kg of herbal composition which consist of:
plant of centaury (Centaurii umbellatum, Gentianaceae) 10- 15% by weight (wt.) root of dandelion (Taraxacum officinale, Asteraceae) 6- 12 % by wt. fruit of juniper (Juniperi communis L, Cupresaceae) 5-8 % by wt. plant of nettle (Urticae dioica L, Urticaceae) 5-10 % by wt. root of nettle ( Urticae dioica L, Urticaceae) 5- 10 % by wt. root of chicory (Cichorium intybus L, Cichoriaceae) 12-20 % by wt. leaf of black mulberry (Morus nigra L, Moraceae) 5-10 % by wt. flower of yarrow (Achilleae millefolium L, Asteraceae) 2-5 % by wt. leaf of bilberry (Vaccinium myrtiϊlus L, Ericaceae) 4-10 % by wt. pod of beans (Phaseolus vulgaris L, Fabaceae) 10-20 % by wt. and root of valerian (Valeriana ojficinalis L, Valerianaceae) 5-10 % by wt. 2) The aforesaid mixture is left to rest for 28 days in a covered container, at the room temperature and pressure. The herbal tincture is then obtained by decanting the liquid above the sediment and filtration of lower layer. Yield is 63 weight %.
3) Obtained alcoholic tincture is entered to apparatus for whirling spray granulation on temperature of 25 ° C. In apparatus alcoholic tincture is to be sprayed with anhydrous air, which has a temperature around 48 ° C. Air was provided in the apparatus with two phase nozzle. In apparatus alcoholic tincture has to be increased in density for factor 5. Spaying with air is applied under pressure of 3 barr. All procedure can be done with WSG-GLATT-50. 282 mg of alcoholic extract produces 56,4 mg dried powder of active substance.
4) Active principle, pulvis powder of herbal mixture, chicory root and Mg- stearate are mixed in weight ratio 16,7 : 37,0 : 45,0 : 1,3 until homogenous mixture. Obtained homogenous mixture is capsulated in gelatinize capsule.
According to the preferred embodiment of invention capsules can consist 200 mg or 480 mg pharmaceutical preparation described above.
In 200 mg capsule we have:
Active principle 33 mg
Pulvis powder 74 mg
Chicory root -90 mg
Mg-stearate 3 mg
In 480 mg capsule we have:
Active principle 79 mg
Pulvis powder 37 mg
Chicory root 216 mg
Mg- stearate 7 mg WAY OF DOSING AND APPLICATION
For diabetes mellitus type II:
1.) In case that a person suffering from diabetes mellitus type II has the glucose level from 4,5 to 7 mmol L, the therapy of one 200 mg capsule twice a day is recommended.
2.) In case that a person suffering from diabetes mellitus type II has the glucose level from 7 to 10 mmol/L, the therapy of one 480 mg capsule twice a day is recommended.
3.) In case that a person suffering from diabetes mellitus type II has the glucose level above 10 mmol/1, the therapy of one 480 mg capsule three time a day is recommended.
For diabetes mellitus type II:
1.) Children younger than 10 years have to take one time a day one 200 mg capsule. 2.) Children older than 10 years have to take one 200 mg capsule twice a day. 3.) Adults that have glucose level above 10 mmol/L have to take one 480 mg capsule once a day. 4.) Adults that have glucose level above 10 mmol/L have to take one 480 mg capsule once or twice a day. 5.) Person suffering from diabetes with insulin resistence need to take capsules as described from 1 to 4. In case of disorders connected with diabetes mellitus: 1.) In case of high cholesterol, therapy of one 200 mg capsule twice a day is recommended. 2.) In case of high triglycerides, therapy of one 480 mg twice a day is recommended.

Claims

1. Process for obtaining of an active substance from: tincture produced by adding 7.21 1 60% ethanol to the each kg of the herbal composition which consist of ground and dried ingredients: plant of centaury (Centaurii umbellatum, Gentianaceae) 10-15% by weight (wt.) root of dandelion (Taraxacum officinale, Asteraceae) 6-12% by wt. fruit of juniper (Juniperi communis L, Cupresaceae) 5-8% by wt. plant of nettle (Urticae dioica L, Urticaceae) 5-10% by wt. root of nettle ( Urticae dioica L, Urticaceae) 5-10% by wt. root of chicory (Cichori m intybus L, Cichoriaceae) 12-20% by wt. leaf of black mulberry (Morus nigra L, Moraceae) 5-10% by wt. flower of yarrow (Achillea millefolium L, Asteraceae) 2-5% by wt. leaf of bilberry (Vaccinium myrtillus L, Ericaceae) 4-10% by wt. pod of beans (Phaseolus vulgaris L, Fabaceae) 10-20% by wt. and root of valerian (Valeriana officinalis L, Valerianaceae) 5-10% by wt. wherein each percentage refers to the total mass of the dried ingredients in the composition, at room temperature, extraction of this mixture in a covered container at the room temperature and pressure for 28 days, decantation of upper layer, filtration of lower layer comprising increasing the density of the herbal mixture by whirling spray granulation with spraying with gas under pressure 1-3 barr, through 30-40 minutes, with provision that temperature of anhydrous gas has to be least 10°C higher than entering temperature of tincture.
2. Process according to the claim 1 characterited by fact that anhydrous air is anhydrous gas for spraying tincture.
3. Process according to the claim 2, characterized by the fact that air is entered in apparatus by two phase nozzle.
4. Process according to the claim 1, characterized by the fact that entering temperature of tincture is 25 ± 5°C.
5. Process according to the claim 1, characterized by the fact that temperature of anhydrous air is 48 ±3°C.
6. Process according to the claim 1, characterized by the fact that density of tincture is to be increased by factor 5.
7. Process according to the claim 1, characterized by the fact that herbal mixture come in process ground on 40±5 mesh.
8. Pharmaceutical preparation comprising active principle obtained according to the claim 1, pulvis powder of herbal mixture, root of chicory and Mg stearate in following weight ratio 16,7 : 37,0 : 0.45: 1,3.
9. Process of obtaining of pharmaceutical composition comprising mixing active principle obtained according to the claim 1, pulvis powder of herbal mixture, chicory root and Mg- stearate until homogenous mixture, and capsulation that mixture in gelatinous capsule.
10. Use of pharmaceutical preparation according to the claim 7, characterized by the factthat it is used for production medicament against diabetes mellitus type I.
EP04769072A 2003-10-10 2004-10-04 Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii) Withdrawn EP1675604A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HRP20030816AA HRP20030816B1 (en) 2003-10-10 2003-10-10 Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii)
PCT/HR2004/000033 WO2005034973A1 (en) 2003-10-10 2004-10-04 Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii)

Publications (1)

Publication Number Publication Date
EP1675604A1 true EP1675604A1 (en) 2006-07-05

Family

ID=46210920

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769072A Withdrawn EP1675604A1 (en) 2003-10-10 2004-10-04 Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii)

Country Status (3)

Country Link
EP (1) EP1675604A1 (en)
HR (1) HRP20030816B1 (en)
WO (1) WO2005034973A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904935A1 (en) * 2006-08-18 2008-02-22 Centre Nat Rech Scient ANTIDIABETIC COMPOSITION CAPABLE OF STIMULATING THE SECRETION OF INSULIN AND INTENDED FOR THE TREATMENT OF DIABETES TYPE 2 (NON-INSULIN-DEPENDENT DIABETES).
HRP20070230B1 (en) * 2007-05-18 2010-05-31 Leko Vlado Herbal composition for the prevention and treatmentofdiabetes mellitus type (i) and type (ii)
CN103223016B (en) * 2013-05-06 2014-09-17 长春三德天晟科技有限公司 Ginseng, mulberry leaf and chicoric acid composition for treating diabetes
CN108524571A (en) * 2018-07-21 2018-09-14 安溪县凤城建金产品外观设计服务中心 The technique of active ingredient in a kind of milfoil by restricted-access media

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363714B (en) * 1998-04-23 2004-03-03 Vladimir Leko Herbal composition and medicament against diabetes mellitus type II manufactured thereof
DE19927537A1 (en) * 1999-06-16 2000-12-21 Merck Patent Gmbh Spray drying plant and method of using it

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005034973A1 *

Also Published As

Publication number Publication date
HRP20030816A2 (en) 2005-06-30
HRP20030816B1 (en) 2012-05-31
WO2005034973A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
US5578307A (en) Shaped articles containing plant extract(s), in particular pellets, and their pharmaceutical or cosmetic use
Amit et al. Phytosome: Phytolipid drug delivery system for improving bioavailability of herbal drug
Fernando et al. Hypoglycaemic activity of some medicinal plants in Sri-Lanka
KR20070065400A (en) Extracts from roots and/or shoots of asparagus officinalis l., their preparation and their use
RU2155062C1 (en) Method of preparing drug with enhanced activity and drug
KR100258642B1 (en) Rapidly dissolving oral dosage form
JP2014031367A (en) Sympathetic nerve activator
RU2474432C2 (en) METHOD FOR PREPARING Pelargonium sidoides AND Pelargonium reniforme EXTRACT
KR100306427B1 (en) Medicinal composition for diabetes
EP1675604A1 (en) Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii)
KR102342819B1 (en) Formulation of a micro drop pill and the preparation method thereof
RU2351354C1 (en) Medication for treatment and prevention of thyroid gland diseases
AU733959B2 (en) Method for preparing an extract of active principles in the form of microgranules based on dietary fibres
CA2128242C (en) Moulded bodies, in particular pellets, containing one or more plant extracts, and the pharmaceutical or cosmetic use of such pellets
CN105362337B (en) A kind of Chinese medicine composition with heat-clearing dissipating bind function, preparation and preparation method thereof
KR19980067592A (en) Chinese herbal compositions and pharmaceutical preparations thereof
ES2603782T3 (en) The use of a surface part of Hedychium Coronarium Koenig in the reduction of blood glucose; extracts and compositions of buried parts of Hedychium Coronarium Koenig and their uses
CN1161105C (en) Flowable drug precursor product for compressing tablet, pill and coated tablet, and preparing method thereof
WO2001054673A1 (en) Method for preparing and administering medicinal plant material
US7074436B2 (en) Method for the production of phyllanthus extracts
CN107373664B (en) Composition with PM2.5 particle resistance effect
CN101716200B (en) Medicinal composition for invigorating circulation blood and dredging collaterals and clearing heat and releasing toxin and preparation method and application thereof
CN110638853A (en) Application of artichoke leaf extract in preparing medicine for lowering blood pressure and composition thereof
CN1370195A (en) Rapidly decomposing chitosan-based pellets
CN100542517C (en) Calculus bovis detoxifying dropping pill and preparation method thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT IT

TCAT At: translation of patent claims filed
DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): AT IT

17Q First examination report despatched

Effective date: 20070926

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/14 20060101AFI20090306BHEP

Ipc: A61K 36/45 20060101ALI20090306BHEP

Ipc: A61K 36/282 20060101ALI20090306BHEP

Ipc: A61P 3/10 20060101ALI20090306BHEP

Ipc: A61K 36/48 20060101ALI20090306BHEP

Ipc: A61K 36/60 20060101ALI20090306BHEP

Ipc: A61K 36/84 20060101ALI20090306BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100501